Trending
- Nanosonics educational platforms promote best practice in ultrasound probe decontamination
- Trade powerlist recognises role of AXREM women
- Grant to help development of Seracam for image-guided surgical oncology
- Improved CT capability will provide better resolution for hybrid imaging at St Helier’s nuclear medicine centre
- Annual inspections can help extend the life of RF doors
- Sheffield’s AI tool predicts kidney failure six times faster than human expert analysts
- Introducing the Omni Legend PETCT scanner at UCLH
- Dr Chatterjee shares POCUS expertise using Probo’s ultrasound system at Arab Health
- Urgent findings from head CT scans prioritised by AI at NHS Greater Glasgow and Clyde to support winter A&E pressures
- AXREM and RAD Magazine announce new partnership
The contribution of hybrid imaging to radionuclide therapy
Author(s): Carla Aberu, Paul Gape, Jan Taprogge, Glen Fluxx
Hospital: The Royal Marsden Hospital, The Institute of Cancer Research
Reference: RAD Magazine, 47, 556, 19
Excerpt: Radionuclide therapy is a rapidly evolving field considered a safe and effective targeted approach to treating many types of cancer. Radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate at the site of treatment by physiological mechanisms. Almost all radionuclides used in radionuclide therapy emit photons that can be imaged, enabling non-invasive visualisation of the biodistribution of the therapeutic agent. The combination of functional imaging in nuclear medicine (SPECT, PET) with anatomical imaging in CT, in what is referred to as hybrid imaging, provides undoubted diagnostic value. After many decades of little growth, a dramatic increase in radiotherapeutics heralds what is promising to be a step change in this area of cancer management.